Clinical Trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Protocol Amendment History 1 change
notable Trial sites expanded: 244 -> 253 locations 2026-05-01
Trial Details
NCT Number NCT05899608
Lead Sponsor Summit Therapeutics
Conditions Non-Small Cell Lung Cancer
Enrollment 1,600 participants
Start Date 2023-10-26
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30